The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease
1Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, GBRC, University of Glasgow, Glasgow G12 8TA, UK. Ashley.Miller@glasgow.ac.uk
Abstract:
Numerous pro-inflammatory cytokines have been implicated in the pathogenesis of several cardiovascular diseases. Interleukin (IL)-33 is a new member of the IL-1 family of cytokines that promotes Th2 type immune responses by signaling through the ST2L and IL-1RAcP dimeric receptor complex. Furthermore, the biological effects of IL-33 are limited by a soluble decoy form of ST2 (sST2). Recent studies indicate a protective role for IL-33 and ST2L in atherosclerosis, obesity and cardiac remodeling. The present review summarizes currently available data showing the role for IL-33 and its receptor ST2L within cardiovascular disease, and the potential use of sST2 as a predictive cardiovascular biomarker.
Related Concept Videos
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Coronary Artery Disease II: Pathophysiology
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Rheumatic Heart Disease III: Medical Management
